Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy

被引:81
作者
Bardazzi, F. [1 ]
Balestri, R. [1 ]
Baldi, E. [2 ]
Antonucci, A. [1 ]
De Tommaso, S. [1 ]
Patrizi, A. [1 ]
机构
[1] Univ Bologna, Div Dermatol, Dept Internal Med Oldness & Nephrol Dis, I-40138 Bologna, Italy
[2] Univ Bologna, Med & Publ Hlth Dept, I-40138 Bologna, Italy
关键词
biological therapy; overweight; obesity; psoriasis; OBESITY; IMPACT;
D O I
10.1111/j.1529-8019.2009.01281.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100227 [皮肤病学];
摘要
Obesity is common in psoriatic patients, and it has been shown to be important for many aspects of the condition. In particular, low-calorie diets can improve the symptoms and response to treatment in pustular psoriasis. The present study investigates the influence of body-weight alteration on the disease's clinical manifestations in moderate to severe psoriasis patients treated with biological drugs. Finally, the influence of a caloric restriction was assessed. This observational transversal study enrolled 33 patients attending our Severe Psoriasis Outpatient Clinic, who were treated with biological drugs. Body Mass Index (BMI) was used as a diagnostic indicator of being overweight and of obesity. Waist circumference was also measured. Body weight and Psoriasis Area Severity Index (PASI) index were measured at follow-up visits at 4 and 8 months. Nonparametric test of Mann-Whitney was used to detect the differences between patient groups. Fisher's exact test was performed to evaluate the different results depending on the therapeutic changes of BMI. There was a strong prevalence of overweight-obese individuals in the group with a mean BMI of 30.59 +/- 6.94. Waist circumference was also above normal in the majority of the patients. Obese patients had a PASI index higher than the average of the whole group (25.03 +/- 12.43), with grade III obese patients having an average PASI of 44 +/- 3.37. At the first and second follow-ups, patients who put on weight did not achieve PASI 50; patients who had a stable weight presented variable response to treatment, while patients who decreased their weight achieved PASI 90 or PASI 75 even when not responding at the first. Further studies are needed to understand if the poor response observed in heavier patients is due to biological drugs pharmacokinetics or because therapy should be BMI based rather than administered in fixed doses, posing then an ethical consideration.
引用
收藏
页码:S14 / S19
页数:6
相关论文
共 7 条
[1]
Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor α treatment [J].
Briot, K ;
Garnero, P ;
Le Henanff, A ;
Dougados, M ;
Roux, C .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) :1137-1140
[2]
Impact of obesity and smoking on psoriasis presentation and management [J].
Herron, MD ;
Hinckley, M ;
Hoffman, MS ;
Papenfuss, J ;
Hansen, CB ;
Callis, KP ;
Krueger, GG .
ARCHIVES OF DERMATOLOGY, 2005, 141 (12) :1527-1534
[3]
A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis [J].
Krueger, GG ;
Papp, KA ;
Stough, DB ;
Loven, KH ;
Gulliver, WP ;
Ellis, CN .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 47 (06) :821-833
[4]
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial [J].
Mease, PJ ;
Goffe, BS ;
Metz, J ;
VanderStoep, A ;
Finck, B ;
Burge, DJ .
LANCET, 2000, 356 (9227) :385-390
[5]
Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis [J].
Naldi, Luigi ;
Addis, Antonio ;
Chimenti, Sergio ;
Giannetti, Alberto ;
Picardo, Mauro ;
Tomino, Carlo ;
Maccarone, Mara ;
Chatenoud, Liliane ;
Bertuccio, Paola ;
Caggese, Eugenia ;
Cuscito, Rosanna .
DERMATOLOGY, 2008, 217 (04) :365-373
[6]
Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review [J].
Sterry, W. ;
Strober, B. E. ;
Menter, A. .
BRITISH JOURNAL OF DERMATOLOGY, 2007, 157 (04) :649-655
[7]
Tumor necrosis factor mediates hepatic growth hormone resistance during sepsis [J].
Yumet, G ;
Shumate, ML ;
Bryant, P ;
Lin, CM ;
Lang, CH ;
Cooney, RN .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2002, 283 (03) :E472-E481